Cargando…

Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients

BACKGROUND: The changes in the platelet-to-lymphocyte ratio (PLR) before and after recombinant tissue plasminogen activator (rtPA) treatment and the time point at which the PLR is a potentially valuable prognostic predictor in patients wit ischemic stroke remain largely unknown. Therefore, the purpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ying-Ying, Wang, Mei-Qi, Wang, Yan, Sun, Xin, Qu, Yang, Zhu, Hong-Jing, Wang, Si-Ji, Yan, Xiu-Li, Jin, Hang, Zhang, Peng, Yang, Yi, Guo, Zhen-Ni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549955/
https://www.ncbi.nlm.nih.gov/pubmed/36225933
http://dx.doi.org/10.3389/fimmu.2022.1000626
_version_ 1784805785653477376
author Sun, Ying-Ying
Wang, Mei-Qi
Wang, Yan
Sun, Xin
Qu, Yang
Zhu, Hong-Jing
Wang, Si-Ji
Yan, Xiu-Li
Jin, Hang
Zhang, Peng
Yang, Yi
Guo, Zhen-Ni
author_facet Sun, Ying-Ying
Wang, Mei-Qi
Wang, Yan
Sun, Xin
Qu, Yang
Zhu, Hong-Jing
Wang, Si-Ji
Yan, Xiu-Li
Jin, Hang
Zhang, Peng
Yang, Yi
Guo, Zhen-Ni
author_sort Sun, Ying-Ying
collection PubMed
description BACKGROUND: The changes in the platelet-to-lymphocyte ratio (PLR) before and after recombinant tissue plasminogen activator (rtPA) treatment and the time point at which the PLR is a potentially valuable prognostic predictor in patients wit ischemic stroke remain largely unknown. Therefore, the purpose of this study was to explore the characteristics of the PLR and evaluate their effects on clinical outcomes before and 24 h after rtPA treatment. METHODS: This study included 741 consecutive patients with acute ischemic stroke who underwent intravenous thrombolysis with rtPA. We collected data on demographics, vascular risk factors, medication history, and other clinical information pertaining to all patients. Specifically, blood samples for PLR measurement were collected on admission and 24 h after stroke. The outcome was assessed by using the Modified Rankin Scale (mRS) at 3 months and whether death occurred within 3 months or not. Univariate and multivariate logistic regression analysis was used to assess the association of the PLR with the risks of poor outcome (mRS>2) and death. An individualized prediction model was established to predict poor outcome. RESULTS: Of the 741 patients, 255 (34.4%) had poor outcome, and 43 (5.8%) died. The PLR significantly increased 24 h after rtPA in patients with poor outcome and death. Logistic analysis revealed that higher PLR 24 h after rtPA was independently associated with increased risks of poor outcome and death. However, the PLR on admission was not associated with the risks of poor outcome and death. The individualized prediction model for poor outcome based on the 24-h PLR exhibited favorable discrimination (areas under the curves of the training and validation groups: 0.743 and 0.729, respectively), calibration (P > 0.05), and clinical usefulness. CONCLUSIONS: We found the PLR to be a variable that potentially predicts the risks of poor outcome and death in patients with acute ischemic stroke 24 h after rtPA; however, it cannot make the same prediction on admission.
format Online
Article
Text
id pubmed-9549955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95499552022-10-11 Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients Sun, Ying-Ying Wang, Mei-Qi Wang, Yan Sun, Xin Qu, Yang Zhu, Hong-Jing Wang, Si-Ji Yan, Xiu-Li Jin, Hang Zhang, Peng Yang, Yi Guo, Zhen-Ni Front Immunol Immunology BACKGROUND: The changes in the platelet-to-lymphocyte ratio (PLR) before and after recombinant tissue plasminogen activator (rtPA) treatment and the time point at which the PLR is a potentially valuable prognostic predictor in patients wit ischemic stroke remain largely unknown. Therefore, the purpose of this study was to explore the characteristics of the PLR and evaluate their effects on clinical outcomes before and 24 h after rtPA treatment. METHODS: This study included 741 consecutive patients with acute ischemic stroke who underwent intravenous thrombolysis with rtPA. We collected data on demographics, vascular risk factors, medication history, and other clinical information pertaining to all patients. Specifically, blood samples for PLR measurement were collected on admission and 24 h after stroke. The outcome was assessed by using the Modified Rankin Scale (mRS) at 3 months and whether death occurred within 3 months or not. Univariate and multivariate logistic regression analysis was used to assess the association of the PLR with the risks of poor outcome (mRS>2) and death. An individualized prediction model was established to predict poor outcome. RESULTS: Of the 741 patients, 255 (34.4%) had poor outcome, and 43 (5.8%) died. The PLR significantly increased 24 h after rtPA in patients with poor outcome and death. Logistic analysis revealed that higher PLR 24 h after rtPA was independently associated with increased risks of poor outcome and death. However, the PLR on admission was not associated with the risks of poor outcome and death. The individualized prediction model for poor outcome based on the 24-h PLR exhibited favorable discrimination (areas under the curves of the training and validation groups: 0.743 and 0.729, respectively), calibration (P > 0.05), and clinical usefulness. CONCLUSIONS: We found the PLR to be a variable that potentially predicts the risks of poor outcome and death in patients with acute ischemic stroke 24 h after rtPA; however, it cannot make the same prediction on admission. Frontiers Media S.A. 2022-09-26 /pmc/articles/PMC9549955/ /pubmed/36225933 http://dx.doi.org/10.3389/fimmu.2022.1000626 Text en Copyright © 2022 Sun, Wang, Wang, Sun, Qu, Zhu, Wang, Yan, Jin, Zhang, Yang and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Sun, Ying-Ying
Wang, Mei-Qi
Wang, Yan
Sun, Xin
Qu, Yang
Zhu, Hong-Jing
Wang, Si-Ji
Yan, Xiu-Li
Jin, Hang
Zhang, Peng
Yang, Yi
Guo, Zhen-Ni
Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
title Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
title_full Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
title_fullStr Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
title_full_unstemmed Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
title_short Platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
title_sort platelet-to-lymphocyte ratio at 24h after thrombolysis is a prognostic marker in acute ischemic stroke patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549955/
https://www.ncbi.nlm.nih.gov/pubmed/36225933
http://dx.doi.org/10.3389/fimmu.2022.1000626
work_keys_str_mv AT sunyingying platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT wangmeiqi platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT wangyan platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT sunxin platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT quyang platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT zhuhongjing platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT wangsiji platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT yanxiuli platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT jinhang platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT zhangpeng platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT yangyi platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients
AT guozhenni platelettolymphocyteratioat24hafterthrombolysisisaprognosticmarkerinacuteischemicstrokepatients